Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
Zymeworks Wins Life Sciences BC 2025 Company of the Year Award
We are pleased to announce that Zymeworks has received Life Sciences BC’s 2025 Company of the Year Award! The award is presented to an outstanding company for its leadership and achievements that are significantly strengthening the BC life sciences sector. It recognizes strong overall performance, excellent execution of business strategies, effective leadership following a clear […]
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference
Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development
